<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H04D331A94696434CAB94162CF53ED9BC" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 4704 IH: Rotary-wing Operator Toxic Occupational Research Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-07-23</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4704</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250723">July 23, 2025</action-date><action-desc><sponsor name-id="M001218">Mr. McCormick</sponsor> (for himself, <cosponsor name-id="D000530">Mr. Deluzio</cosponsor>, <cosponsor name-id="P000048">Mr. Pfluger</cosponsor>, <cosponsor name-id="D000230">Mr. Davis of North Carolina</cosponsor>, <cosponsor name-id="W000804">Mr. Wittman</cosponsor>, <cosponsor name-id="M001196">Mr. Moulton</cosponsor>, <cosponsor name-id="K000399">Mrs. Kiggans of Virginia</cosponsor>, <cosponsor name-id="B001298">Mr. Bacon</cosponsor>, <cosponsor name-id="K000389">Mr. Khanna</cosponsor>, <cosponsor name-id="M001157">Mr. McCaul</cosponsor>, <cosponsor name-id="G000592">Mr. Golden of Maine</cosponsor>, and <cosponsor name-id="F000475">Mr. Finstad</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HAS00">Committee on Armed Services</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Director of the Defense Health Agency to conduct a study on the prevalence and mortality of cancer among military rotary wing pilots and aviation support personnel, and for other purposes.</official-title></form><legis-body id="H9BA3087E264D4BFE8A762DBC31EE0FFC" style="OLC">
<section id="H887A6EFA8D1547BEAD41823169B8373E" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Rotary-wing Operator Toxic Occupational Research Act</short-title></quote> or the <quote><short-title>ROTOR Act</short-title></quote>.</text></section> <section id="HD89447DFE63145BCBCF8500C2781F7D2"><enum>2.</enum><header>Study on prevalence and mortality of cancer among military rotary-wing pilots and aviation support personnel</header> <subsection id="H6C7D4787F7F2471B8027201DEAF316E5" display-inline="no-display-inline"><enum>(a)</enum><header>Study required</header><text>The Director of the Defense Health Agency, in coordination with the Directors of the National Institutes of Health and the National Cancer Institute, shall conduct a study among covered individuals in two phases as provided by this section.</text></subsection>
<subsection id="H23F4B3E2AD58492A9EA87F411886C69D"><enum>(b)</enum><header>Initial phase of study</header>
<paragraph id="HA22959321A86417FA92A8072C9FD5DDC"><enum>(1)</enum><header>Goal of initial phase</header><text display-inline="yes-display-inline">Under the initial phase of the study under subsection (a), the Director of the Defense Health Agency shall determine, for each cancer specified in paragraph (2), whether there is an increased prevalence of, or increased rate of mortality caused by, such cancer for covered individuals as compared to similarly aged individuals in the general population (or, in the case of the cancer specified in paragraph (2)(B), for female covered individuals as compared to similarly aged women in the general population).</text></paragraph> <paragraph id="HC4C41A14D3DD473B9AE1F0F8E0CD6641"><enum>(2)</enum><header>Cancers specified</header><text>The cancers specified in this paragraph are the following:</text>
<subparagraph id="H42995DDACCB74D0199C4B5A18DA7459C"><enum>(A)</enum><text>Brain cancer.</text></subparagraph> <subparagraph id="HE2D166191B8C4FBA9CA686DA578079E2"><enum>(B)</enum><text>Breast cancer.</text></subparagraph>
<subparagraph id="HE2C2B07E59DD45A5B47C1D1CBAC24AD6"><enum>(C)</enum><text>Colon and rectal cancer.</text></subparagraph> <subparagraph id="H6182413946EA4D23ACD90791424B2BD4"><enum>(D)</enum><text>Kidney cancer.</text></subparagraph>
<subparagraph id="H7D6FD0778B6A483784469D3F0E49079F"><enum>(E)</enum><text>Lung cancer.</text></subparagraph> <subparagraph id="H7EB043E683DA44AD9F16331896911BC9"><enum>(F)</enum><text>Melanoma.</text></subparagraph>
<subparagraph id="H7DAB6514C2B64D0A9BB9AE26E2705BE9"><enum>(G)</enum><text>Non-Hodgkin’s lymphoma.</text></subparagraph> <subparagraph id="HEEC1629343AB4D48AA02BEBDCD301703"><enum>(H)</enum><text>Ovarian cancer.</text></subparagraph>
<subparagraph id="H94418B370FA543A9A819667D5310AEF8"><enum>(I)</enum><text>Pancreatic cancer.</text></subparagraph> <subparagraph id="H037782C54D3842AAA2A0440909B7A98E"><enum>(J)</enum><text>Prostate cancer.</text></subparagraph>
<subparagraph id="H409406819717428DA6C524BB9410A2C4"><enum>(K)</enum><text>Testicular cancer.</text></subparagraph> <subparagraph id="H523405DEFEC2423085E398773AD09565"><enum>(L)</enum><text>Urinary bladder cancer.</text></subparagraph></paragraph>
<paragraph id="H133DE6BFB71D488483D992309282438B"><enum>(3)</enum><header>Report on initial phase</header><text>Not later than one year after the date of the enactment of this Act, the Director of the Defense Health Agency shall submit to the appropriate congressional committees a report on the findings of the phase of the study under this subsection.</text></paragraph></subsection> <subsection id="H355C30BD85D84BBF84FB855B43A144EC"><enum>(c)</enum><header>Second phase of study</header> <paragraph id="HDE963F1A5B954425ADC3F912CC967D30"><enum>(1)</enum><header>Goal of second phase</header><text display-inline="yes-display-inline">If, pursuant to the phase of the study under subsection (b), the Director of the Defense Health Agency determines there is an increased prevalence of, or increased mortality rate caused by, any cancer specified in subsection (b)(2) among covered individuals (or, with respect to the cancer specified in subsection (b)(2)(B), among female covered individuals), the Director shall conduct a second phase of the study to—</text>
<subparagraph id="H7E298D4EE2B14570929BA3FC719C35B2"><enum>(A)</enum><text display-inline="yes-display-inline">identify any carcinogenic toxin or other hazardous material associated with the operation of military rotary-wing aircraft, such as fumes, fuels, or other liquids;</text></subparagraph> <subparagraph id="H9EB7E69238924AAD80D5340E95ADA1BB"><enum>(B)</enum><text>identify any operating environment, including frequencies or electromagnetic fields, in which covered individuals may have received excess exposure to non-ionizing radiation in the course of such operation, including non-ionizing radiation associated with airborne, ground, or shipboard radars; and</text></subparagraph>
<subparagraph id="H602E8E9A175C436381100EFD4B76B3E9"><enum>(C)</enum><text display-inline="yes-display-inline">identify potential exposures as a result of military service by covered individuals to carcinogenic toxins or other hazardous materials not associated with the operation of military rotary-wing aircraft (such as exposure to burn pits, toxins in contaminated water, or toxins embedded in soils), including by determining—</text> <clause id="H6050B1EA4F4F4C589697B06A02BAF73E"><enum>(i)</enum><text>the locations of such service; and</text></clause>
<clause id="H1E08EDBB1F844AEA8844E582A5BB26A6"><enum>(ii)</enum><text display-inline="yes-display-inline">any duties of covered individuals unrelated to such operation and associated with an increased prevalence of, or increased mortality rate caused by, cancer.</text></clause></subparagraph></paragraph> <paragraph id="H567E31F6649B452E87D0EAB841DE0301"><enum>(2)</enum><header>Report on second phase</header><text display-inline="yes-display-inline">If the Director of the Defense Health Agency conducts the phase of the study under this subsection, not later than one year after the date on which the Director submits the report under subsection (b)(3), the Director shall submit to the appropriate congressional committees a report on the findings of such phase.</text></paragraph>
<paragraph id="HFE450F0A55E143D78951F4159774AD2B"><enum>(3)</enum><header>Data format</header><text>The Director of the Defense Health Agency shall format any data resulting from the phase of the study under this subsection consistent with the formatting of data under the Surveillance, Epidemiology, and End Results program, including by disaggregating such data by race, gender, and age.</text></paragraph></subsection> <subsection id="H8CFAACD215E14581A773BE0C8455CE54"><enum>(d)</enum><header>Sources of data</header><text>In conducting the study under this section, the Director of the Defense Health Agency shall use data from—</text>
<paragraph id="HAA7F0AB3333D49DF814B3F123CBA1296"><enum>(1)</enum><text display-inline="yes-display-inline">the database of the Surveillance, Epidemiology, and End Results program;</text></paragraph> <paragraph id="HEA8AB7548F7A4437A92D41F37148096B" display-inline="no-display-inline"><enum>(2)</enum><text display-inline="yes-display-inline">the study conducted under section 750 of the National Defense Authorization Act for Fiscal Year 2021 (<external-xref legal-doc="public-law" parsable-cite="pl/116/283">Public Law 116–283</external-xref>; 134 Stat. 3716); and</text></paragraph>
<paragraph id="H0B18857F3C9048B2BACA3C1BE986515F"><enum>(3)</enum><text>any other study previously conducted by the Secretary of a military department that the Director determines relevant for purposes of this section.</text></paragraph></subsection> <subsection id="H155A03707C864F71B166DA5A58C4E5B0"><enum>(e)</enum><header>Definitions</header><text>In this section:</text>
<paragraph id="H6C6C7951130F485B8054695ABE1DECB0"><enum>(1)</enum><text>The term <quote>appropriate congressional committees</quote> means—</text> <subparagraph id="HEF27A58E78514FADA6BCCB38FFD1639F"><enum>(A)</enum><text>the Committee on Armed Services and the Committee on Veterans’ Affairs of the House of Representatives; and</text></subparagraph>
<subparagraph id="H115F199474BB4348924EA1397000B713"><enum>(B)</enum><text>the Committee on Armed Services and the Committee on Veterans’ Affairs of the Senate.</text></subparagraph></paragraph> <paragraph id="H06F17A7A994D44FB9547ED0DE4A7BE10"><enum>(2)</enum><text display-inline="yes-display-inline">The term <quote>covered Armed Force</quote> means the Army, Navy, Marine Corps, Air Force, or Space Force.</text></paragraph>
<paragraph id="H7C405680563541E0B26660BBFE41EE2F"><enum>(3)</enum><text>The term <quote>covered individual</quote> means any individual who—</text> <subparagraph id="H86AA3955766F4ADA9517CBFA705493C4"><enum>(A)</enum><text display-inline="yes-display-inline">served in a covered Armed Force on or after February 28, 1961, as an aircrew member of a rotary-wing aircraft (including as a pilot or aviation support personnel), without regard to the status, position, rank, or grade of the individual within such crew; and</text></subparagraph>
<subparagraph id="H02AE842E961E41519B9782F71489F230"><enum>(B)</enum><text>receives health care benefits under <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/10/55">chapter 55</external-xref> of title 10, United States Code.</text></subparagraph></paragraph> <paragraph id="H40EC2BC63B4C4F65828328B2A26AB881"><enum>(4)</enum><text>The term <quote>Surveillance, Epidemiology, and End Results program</quote> means the program of the National Cancer Institute referred to in section 399B(d)(1) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/40/280e">40 U.S.C. 280e(d)(1)</external-xref>), or any successor program.</text></paragraph></subsection></section> 
</legis-body></bill>

